• Explore /
  • Poster
  • / <span>Nucleosome profiling at AR binding sites (ARBS) to provide a prognostic tool for metastatic castration-resistant prostate cancer (mCRPC).</span>

Nucleosome profiling at AR binding sites (ARBS) to provide a prognostic tool for metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Chao Dai

Predicine, Inc., Hayward, CA

Chao Dai , Lisha Zhu , Heidi Fettke , Shuang Gan , Pan Du , Shidong Jia , Arun Azad

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Diagnostics and Imaging

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 42)

DOI

10.1200/JCO.2024.42.4_suppl.42

Abstract #

42

Poster Bd #

A21

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Genitourinary Cancers Symposium

Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.

Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.

First Author: Alice Bernard-Tessier

First Author: Arpit Rao

First Author: Arpit Rao

First Author: David D. Chism